BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
Investor Relations
Stock price graph

We are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own partnerships of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). The Company has collaborated or is collaborating with Amgen, Pfizer, AstraZeneca, and Roche to develop Accurins based on therapeutic payloads from their product pipelines.

View all »   RSSRecent Releases

Oct 30, 2014
BIND Therapeutics Announces Availability of Abstract with Preliminary Data from Phase 2 Study of BIND-014 in Non-small Cell Lung Cancer

Oct 29, 2014
BIND Therapeutics to Present at November Healthcare Conferences

View all »Events & Presentations

Nov 6, 2014 at 8:30 AM ET
BIND's Third Quarter 2014 Financial Results

Nov 12, 2014 at 3:30 PM MT
Credit Suisse 2014 Healthcare Conference

Nov 19, 2014 at 8:35 AM ET
Stifel Nicolaus Weisel Healthcare Conference


NASDAQ: BIND
Price:
8.94
Change:
+ 1.11
Day High:
9.10
Day Low:
7.87
Volume:
242,300
4:00 PM ET on Oct 30, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Media Inquiries
Direct media inquiries to:
Gina Nugent
The Yates Network
gina@theyatesnetwork.com

Investor Inquiries
Direct investor inquiries to:
Paul Cox
Stern Investor Relations
212-362-1200
BIND@sternir.com